Remove Antibody Remove Drug Delivery Remove Drug Delivery Systems Remove Marketing
article thumbnail

Subcutaneous Medications and Drug Delivery Systems

Roots Analysis

In fact, the share of biologics in the overall pharmaceutical contract manufacturing market has increased from 16% in 2006 to over 25% in 2017. Having reported over 70% increase in revenues over the past 5-6 years, the market for biologically derived products is currently estimated to be worth more than USD 200 billion.

article thumbnail

Subcutaneous Biologics: The Unmet Requirement in the Pharmaceutical Space

Roots Analysis

However, several drug delivery devices that enable patients to self-administer their respective medications are now available. Subcutaneous biologics – current market landscape. Subcutaneous drug delivery systems – the helping hand for patients. Of these, 50 players have approved subcutaneous biologics.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Exosomes: A Deeper Look into Service Providers Market

Roots Analysis

In order to promote the use of exosomes in various therapeutic applications including targeted drug delivery vehicles, engineered exosomes and many more, there are a number of companies that offer services related to the isolation, purification, characterization or quantification of exosomes. Want additional details on the pipeline?

article thumbnail

New Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030

Roots Analysis

To learn more, please click New Frontiers Cancer Therapy market report. Types of Molecules and Regions Worldwide Overall, the growth is anticipated to be spread across multiple type of molecules and different geographical regions. For any queries / suggestions, please do not hesitate to contact us at sales@rootsanalysis.com.

article thumbnail

Genentech’s New Ocular Implant Drug Delivery System for Macular Degeneration Could Be a Game Changer

XTalks

Genentech’s ocular implant drug delivery system for treatment of macular degeneration has received approval from the US Food and Drug Administration (FDA). Susvimo delivers ranibizumab via a port delivery system into a surgically placed implant in the eye, allowing for continuous delivery of the drug.

article thumbnail

Biopharmaceutical Excipient Manufacturing – Current Scenario and Future Trends

Roots Analysis

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Future Evolution of Biopharmaceutical Excipient Manufacturing Market.

article thumbnail

Next Generation Complement Therapeutics: Potential Life-Changing Therapies for Multiple Rare Disorders

Roots Analysis

Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Next Generation Complement Therapeutics – Current Market Landscape. The market is characterized by a mix of well-established and small firms. Next Generation Complement Therapeutics Market.